Advisory Research Inc. Takes $1.11 Million Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Posted by Defense World Staff on Mar 15th, 2023

Advisory Research Inc. acquired a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 31,726 shares of the company’s stock, valued at approximately $1,108,000. Advisory Research Inc. owned approximately 0.06% of Ventyx Biosciences as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Ventyx Biosciences by 152.3% in the 2nd quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock valued at $30,000 after buying an additional 1,462 shares in the last quarter. High Net Worth Advisory Group LLC increased its position in shares of Ventyx Biosciences by 100.0% during the 3rd quarter. High Net Worth Advisory Group LLC now owns 1,000 shares of the company’s stock worth $35,000 after purchasing an additional 500 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of Ventyx Biosciences during the 2nd quarter worth about $97,000. American International Group Inc. increased its position in shares of Ventyx Biosciences by 102.3% during the 2nd quarter. American International Group Inc. now owns 10,490 shares of the company’s stock worth $128,000 after purchasing an additional 5,305 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new stake in shares of Ventyx Biosciences during the 2nd quarter worth about $132,000. Institutional investors and hedge funds own 95.57% of the company’s stock.

Insider Activity

In other news, CEO Raju Mohan sold 55,354 shares of the firm’s stock in a transaction dated Thursday, December 22nd. The shares were sold at an average price of $31.61, for a total value of $1,749,739.94. Following the transaction, the chief executive officer now owns 1,603,126 shares of the company’s stock, valued at approximately $50,674,812.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider John Nuss sold 13,812 shares of the firm’s stock in a transaction dated Thursday, December 22nd. The shares were sold at an average price of $31.61, for a total value of $436,597.32. Following the transaction, the insider now owns 244,815 shares of the company’s stock, valued at approximately $7,738,602.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 55,354 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 22nd. The stock was sold at an average price of $31.61, for a total transaction of $1,749,739.94. Following the transaction, the chief executive officer now directly owns 1,603,126 shares in the company, valued at approximately $50,674,812.86. The disclosure for this sale can be found here. In the last quarter, insiders have sold 402,519 shares of company stock valued at $13,341,655. 49.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Ventyx Biosciences in a research report on Monday, December 19th. They set a “buy” rating and a $50.00 target price for the company. Morgan Stanley assumed coverage on shares of Ventyx Biosciences in a research report on Thursday, November 17th. They set an “overweight” rating and a $45.00 target price for the company. Canaccord Genuity Group increased their target price on shares of Ventyx Biosciences from $35.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, January 31st. Oppenheimer increased their price objective on shares of Ventyx Biosciences from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Friday, January 27th. Finally, Evercore ISI increased their price objective on shares of Ventyx Biosciences from $50.00 to $65.00 in a report on Thursday, January 26th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $52.78.

Ventyx Biosciences Stock Down 0.9 %

Shares of NASDAQ VTYX opened at $37.84 on Wednesday. Ventyx Biosciences, Inc. has a 1 year low of $9.76 and a 1 year high of $47.25. The firm’s 50-day moving average is $39.85 and its 200-day moving average is $33.39.

Ventyx Biosciences Company Profile

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Advisory Research Inc. Takes $1.11 Million Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Insider Activity

Analysts Set New Price Targets

Ventyx Biosciences Stock Down 0.9 %

Ventyx Biosciences Company Profile

See Also

You might be interested in: